Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preladenant in Moderate to Severe Parkinson's Disease
NCT01155466Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2010
- Primary completion
- Dec 2012
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of preladenant in Parkinson's disease (PD) (5 arms), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Mean 'Off' Time at 12 weeks, Number of Participants With Systolic Blood Pressure >=180 mm Hg at 14 weeks and 5 more. Started Jul 2010; status: completed.
02
Drugs
preladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01155466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01155466.